All Industry Workshops take place on Tuesday, October 23, 2018 from 11:30 am – 12:30 pm. 

AMCP Industry Workshops with a   include preapproval information exchange information.  Subject to federal laws and regulations, attendance at these sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. For more information, visit our website.

The Changing Landscape of Alzheimer’s Disease

Hosted by Biogen and Eisai
Room: Crystal J1

As more of the United States population ages, Alzheimer’s disease continues to grow as a national healthcare concern. This session will review the burden of Alzheimer’s disease on the managed care system, as well as identify the potential cost drivers of care. The session will also provide an overview of biomarkers and the evolving understanding of Alzheimer’s disease. Furthermore, with potential new disease-modifying therapies on the horizon, the session will explore the potential impact of early diagnosis and treatment. Biogen and Eisai, the Industry Workshop sponsors, will also discuss their commitment to patients with Alzheimer’s disease. This program is open only to representatives of payers, formulary committees, or other similar entities who have responsibility for the selection of drugs for coverage or reimbursement.

09/18    ALZ-US-0018

Babak Tousi, MD, FACP, CMD
Director and Head of Clinical Trials
Cleveland Clinic Lou Ruvo Center for Brain Health


Perspectives in Pain: Findings From the Second Edition of the Pain Trends Report

Provided by Daiichi Sankyo, Inc.
Room: Canary 3-4

In the 2 years since Daiichi Sankyo, Inc., published the first edition of the Pain Trends Report, the pain category has undergone significant transformation. Drawn from the insights of those deeply immersed in pain management, the second edition of the report discusses important topics in the pain category and how the landscape continues to evolve. Surveyed stakeholders included national and regional payers, clinicians, and employers, all of whom had experience in managing or treating the various forms of pain. This presentation provides an overview of the Pain Trends Report and highlights key survey findings. Topics of interest include payer and employer strategies to reduce pain management costs, changes in clinician prescribing of pain medications, and how different stakeholders are addressing opioid abuse. The presentation also discusses the unmet needs in neuropathic pain and shares clinicians’ and payers’ views of current treatment options.
©2018 Daiichi Sankyo, Inc.

08/18      PP-US-PAIN-0275

Linda Vanni, MSN, RN-BC, ACNS-BC, NP, AP-PMN
Nurse Practitioner
Professional Pain Education & Consulting, LLC


Addressing Challenges in the Treatment of Type 2 Diabetes: The role of Fixed-dose and Fixed-ratio Combination Therapies

Provided by Sanofi
Room: Canary 1-2

T2DM is a chronic disease caused by defects in various organs, including a progressive decline in the beta-cell’s ability to produce insulin. It is a disorder that requires significant vigilance and frequent interventions to achieve and sustain glucose control. Health plans & PBMs are faced with navigating an increasing number of therapies to treat glucose control, while challenged by therapeutic inertia and low rates of medication adherence that result in patients not achieving these goals. These factors result in prolonged periods of hyperglycemia/hypoglycemia, increasing the risks of diabetes complications. Several classes of antihyperglycemic agents are available that can be used in combination with complementary mechanisms of action to help safely achieve normal glycemia, such as the fixed-ratio combinations of basal insulin and GLP-1 receptor agonists. We will discuss the role of these antihyperglycemic combinations in addressing the challenges facing clinicians and patients in attaining optimal glucose control.

Juan Pablo Frias, M.D., FACE
President and CEO
National Research Institute
Los Angeles, CA